AstraZeneca announced that, effective 1 June 2017, the Board has appointed Professor Nazneen Rahman as a Non-Executive Director of AstraZeneca PLC. On appointment, Professor Rahman also becomes a member of the Science Committee.
Professor Nazneen Rahman is Head of the Division of Genetics and Epidemiology at the Institute of Cancer Research (ICR), London; Head of the Cancer Genetics Unit at the Royal Marsden NHS Foundation Trust; and Director of the TGL clinical gene testing laboratory at the ICR. She qualified in medicine from Oxford University and holds a PhD in molecular genetics, according to AstraZeneca.
Professor Rahman’s research harnesses her scientific and clinical expertise to identify and clinically implement human disease genes. She has a strong focus on cancer predisposition genes, in which she is an internationally-recognised expert and has discovered many such genes during her career, particularly for breast, ovarian and childhood cancers.
Elected as a Fellow of the Academy of Medical Sciences in 2010, Professor Rahman is a member of the scientific advisory boards of Genomics plc and the Centre for Molecular Medicine Norway, as well as the advisory board of Wellcome Open Research.
Professor Rahman has a strong commitment to open science and science communication and has garnered numerous awards, including a CBE in the 2016 Queen’s birthday honours in recognition of her contribution to medical sciences.
Leif Johansson, Chairman of AstraZeneca, said: “We are delighted to welcome Professor Rahman to our Board and Science Committee. She brings world-renowned expertise in genetic research with a focus on cancer, which is a strategic therapy area for our business.”
In relation to Professor Rahman’s appointment, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority’s Listing Rules.
Source: The Financial
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
